

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07C 237/24, C07D 233/54, A61K 31/16, 31/4164, A61P 31/00, 35/00		A1	(11) International Publication Number: WO 00/68185 (43) International Publication Date: 16 November 2000 (16.11.00)
(21) International Application Number: PCT/US00/12888		Venue, Arlington, MA 02476 (US). LOKEY, Scott [US/US]; 199 Auburn Street, Cambridge, MA 02139 (US).	
(22) International Filing Date: 12 May 2000 (12.05.00)		(74) Agents: SAXE, Bernhard, D. et al.; Foley & Lardner, Suite 500, 3000 K Street, N.W., Washington, DC 20007-5109 (US).	
(30) Priority Data: 60/134,076 12 May 1999 (12.05.99) US		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/134,076 (CIP) Filed on 12 May 1999 (12.05.99)		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): COEN, Donald [US/US]; 368 Main Street, Medfield, MA 02052 (US). HOGLE, James [US/US]; 32 Leonard Avenue, Newton, MA 02165 (US). ELKIN, Carl [US/US]; 1657 Cambridge Street, Apartment 1, Cambridge, MA 02138 (US). ZUCCOLA, Harmon, J. [US/US]; 1887 Beacon Street #4, Brookline, MA 02445 (US). BRIDGES, Kristie, Grove [US/US]; 17 Lockeland Av-			
(54) Title: A STRUCTURE-BASED APPROACH TO DESIGN INHIBITORS OF PROTEIN-PROCESSIVITY FACTOR INTERACTIONS			
(57) Abstract			
A method for the structure-based identification and selection of inhibitors of processivity factor binding to protein is disclosed herein. Characterization of the protein/processivity factor interface is given. Methods for the structure-based inhibition of processivity factor binding to protein are also given. One embodiment includes a class of peptidomimetics that mimic helical portions of proteins. In addition, methods of treatment of various diseases are given, using the inhibitors of the invention.			

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

A STRUCTURE-BASED APPROACH TO DESIGN INHIBITORS OF PROTEIN-PROCESSIVITY FACTOR INTERACTIONS

BACKGROUND OF THE INVENTION

1. Field of the Invention

The instant invention is drawn to a method for the structure-based design
5 of inhibitors of DNA polymerase, and DNA repair enzymes, to methods for inhibiting DNA replication and repair, and to methods for treating viral infections, bacterial infections, fungal infections, protozoan infections, and neoplastic diseases.

10 2. Description of the Related Art

15 The herpesviruses, herpes simplex virus (HSV), and human cytomegalovirus (CMV), are two important human pathogens. HSV causes a spectrum of diseases in immunocompetent adults including debilitating genital infections, sight-threatening ocular infections and occasionally encephalitis that is also debilitating and can be fatal if untreated (Corey, L., and P.C. Spear. 1986
N. Engl. J. Med. 314, 686-691.). In newborns and immunosuppressed individuals such as AIDS patients, HSV infections are even more severe. CMV causes little disease in immunocompetent adults, but it is a major cause of birth defects and a major pathogen in immunosuppressed individuals, especially AIDS
20 and transplant patients (Britt, W.J., and C.A. Alford. 1996. Cytomegalovirus, 3rd Edition ed. *In* Fields Virology. B.N. Fields, D.M. Knipe, P.M. Hawley, R.M. Chanock, J.L. Melnick, T.P. Monath, B. Roizman and S.E. Straus, editors. Lippincott-Raven, Philadelphia. 2493-2523). There is also evidence for a role of CMV in cardiovascular diseases (e.g., Zhou et al. 1996 N. Engl. J. Med.
25 335, 624-630.).

Ideally, a target for an antiviral drug should be a viral gene product that differs significantly from host functions and is either essential for viral replication or can activate a drug that inhibits viral replication. Most antiherpesvirus drugs developed to date have targeted herpesvirus thymidine 5 kinases (TK) to activate drugs, and herpesvirus DNA polymerases to be inhibited by the drugs (Coen, D.M. 1992. *Sem. Virol.* 3, 3-12). For example, HSV TK, which is not essential for replication in cell culture, activates acyclovir (ACV) by phosphorylation to its monophosphate much more efficiently than do cellular enzymes. Cellular enzymes convert the monophosphate to the triphosphate, 10 which is a selective and potent inhibitor of HSV DNA polymerase (Pol), which is essential for replication. That TK and Pol serve as selective drug targets has been established both by biochemical studies and by the isolation and analyses of drug resistant mutants (Coen, D.M. 1986 *J. Antimicrob. Chemother.* 18, 1-10).

However, nearly all drug-resistance Pol mutations map in regions 15 encoding regions of Pol that are conserved with human cellular DNA polymerases (Coen, D.M. 1996. In *Antiviral Drug Resistance*. D. Richman, editor. John Wiley & Sons, Chichester. 81-102). Thus, these antiviral drugs appear to exploit only rather subtle differences between viral and cellular and polymerases. Moreover, there are HSV infections for which these drugs are not 20 particularly efficacious and there remain concerns about the potential for toxic effects over the lifetime of a patient and the increasing number of cases in which resistance to these drugs develops (Safrin, S. 1996. In *Antiviral Drug Resistance*. D.D. Richman, editor. John Wiley & Sons, Chichester. 103-122).

In an alternative investigative approach, other polymerase sites are 25 targeted for inhibition. Within this approach, it has been observed that herpesviruses require a specific interaction between HSV DNA polymerase and a processivity factor to effect synthesis of long strands of DNA. In the case of HSV, the accessory proteins, UL42, functions by increasing processivity (Gottlieb et al., 1990 *J. Virol.* 64, 5976-5987). Both Pol and UL42 are essential 30 for virus replication and this essentiality extends to the analogous proteins encoded by other herpesviruses that have been examined. Mutations that specifically disrupt HSV Pol-UL42 interactions block long chain DNA synthesis

and viral replication indicating that these interactions are essential for virus replication (Digard et al., 1993 *J. Virol.* 67, 398-406; Digard et al., 1993 *J. Virol.* 67, 1159-1168). The segment of Pol that interacts with UL42 has been mapped to the C-terminus of the enzyme by a combination of genetic and 5 biochemical methods (Digard et al., 1993 *J. Virol.* 67, 398-406; Digard P., and Coen, D.M. 1990 *J. Biol. Chem.* 265, 17393-17396; Marsden et al., 1994 *J. Gen. Virol.* 75(Pt 11), 3127-3135.; Stow et al., 1993 *Nucleic Acids Res.* 21(1), 87-92.; Tenney et al., 1993 *J. Virol.* 67(1), 543-547.) Peptides corresponding to the C-terminal segment of Pol specifically block long chain DNA synthesis by 10 Pol-UL42 in vitro (Digard et al., 1995 *Proc. Natl. Acad. Sci.* 92, 1456-1460.; Marsden et al., 1994 *J. Gen. Virol.* 75(Pt 11), 3127-3135.) and interfere with HSV infectivity in tissue culture (Loregian et al., 1999, *Proc. Natl. Acad. Sci.* 96: 5221-5226). This segment of Pol is partially helical (Digard et al., 1995 *Proc. Natl. Acad. Sci.* 92, 1456-1460.) but there has been no information about 15 the structure of UL42.

The best understood processivity factors are known as sliding clamps, which include the *Escherichia coli* β-subunit of DNA polymerase III, bacteriophage T4 and RB69 gp45, and the eukaryotic clamp, PCNA. These proteins do not bind directly to DNA but, rather, form multimeric rings around 20 DNA, which permits them to slide along the template. Moreover, under physiological conditions, the association of a sliding clamp with DNA and its cognate polymerase requires auxiliary proteins that serve as "clamp loaders" (Kuriyan, J., and O'Donnell, M. 1993 *J. Mol. Biol.* 234, 915-925.). UL42 differs from sliding clamps in that it binds directly and stably to DNA and does 25 not require additional factors to load onto Pol or DNA (Gottlieb, J., and Challberg, M.D. 1994 *J. Virol.* 68, 4937-4945; Marsden et al., 1987 *J. Virol.* 61, 2428-2437; Powell, K.L., and Purifoy, D.J.M. 1976 *Intervirol.* 7, 225-239; Weisshart et al., 1999 *J. Virol.* 73, 55-66). There have been two reports of structures of processivity factors bound to peptides: 1) human PCNA complexed 30 with a 22 residue peptide derived from the C-terminus of the cell cycle checkpoint protein p21 (Gulbis et al., 1996 *Cell* 87, 297-306); and 2) gp45 from the phage RB69 complexed with a C-terminal peptide fragment of the RB69

DNA polymerase (protein data base 1B77 1B8H; Shamu et al., 1999, Cell, 99:155-166).

Accordingly, the interaction between processivity subunits and proteins whose functions depend upon processivity factor binding, may be an especially 5 amenable drug target relative to other protein-protein interactions. However, many protein-protein interactions involve large surfaces which involve multiple binding site interactions. Accordingly, an effective method by which structure-based design of molecules inhibiting binding between proteins and a processivity factor subunit is desired. Moreover, a method for treating infections (i.e., viral, 10 bacterial, fungal) and methods for treating cancer and tumor growth with structure-based design inhibitors of processivity factor binding are particularly desired.

SUMMARY OF THE INVENTION

15

It is therefore an object of the present invention to provide methods for the structure-based design of inhibitors of processivity factor binding to proteins.

In accomplishing the foregoing object of the invention, there is provided, in accordance with one aspect of the invention, a method for inhibiting 20 processivity factor binding to a protein whose function is modified by the binding of said processivity factor, comprising:

(a) identifying binding sites on said protein or a processivity factor that binds to said protein;

(b) targeting as a site for inhibition, at least one binding site, 25 based upon the identification made in (a);

(c) identifying a library of compounds that are capable of binding to said binding sites; and

(d) screening said library to identify inhibitors of said binding sites.

30 In another aspect of the invention, there is provided, identifying and selecting potential inhibitors of processivity factor binding to a protein comprising the foregoing method of the instant invention.

In yet another aspect of the invention, there is provided, a structure-based method for method for treating a viral, bacterial or fungal mediated infection comprising administering to an animal in need thereof a compound obtained by the foregoing method of the instant invention.

5 In yet another aspect of the invention, there is provided, a method for treating cancer or inhibiting tumor growth comprising administering to an animal in need thereof a compound obtained by the foregoing method of the instant invention.

10 In yet another aspect of the invention, there is provided, a structure-based method for identifying and selecting potential inhibitors of a DNA polymerase, comprising:

15 (a) modeling a target processivity factor based on a template selected from experimentally derived processivity factor structures, wherein said modeling comprises:(i) aligning the primary sequence of said target processivity factor sequence on the sequence of said template by pair-wise, structure-based or multiple sequence alignment to achieve a maximal homology score, followed by repositioning gaps to conserve regular secondary structures; (ii) transposing said aligned sequence to the three dimensional structure of said template to derive the three-dimensional structure of said target processivity factor; (iii) subjecting the 20 structure obtained in step (iv) to energy minimization; and (v) identifying binding sites in said model based upon corresponding binding sites from said experimentally derived processivity factor structures;

(b) targeting as a site for inhibition, at least one amino acid in said binding site, based upon the identification made in (a);

25 (c) identifying a library of compounds that are capable of binding to said binding sites; and

(d) screening said library to identify inhibitors of said binding sites.

30 In yet another aspect of the invention, there is provided, a structure-based method for identifying and selecting potential inhibitors of a DNA polymerase, comprising:

- (a) modeling a target processivity factor based on a template selected from experimentally derived processivity factor structures, wherein said modeling comprises: using computer-based tools predicting secondary structure in said target based upon secondary structure in said template to provide a three dimensional model of said target; and identifying binding sites in said model based upon corresponding binding sites from said template;
- 5 (b) targeting as a site for inhibition, at least one amino acid in said binding site, based upon the identification made in (a);
- (c) identifying a library of compounds that are capable of 10 binding to said binding sites; and
- (d) screening said library to identify inhibitors of said binding sites.

In a preferred embodiment, the protein is a DNA polymerase.

15 In yet another preferred embodiment inhibitors are selected from the group consisting of a peptide, a peptidomimetic and a non-peptide small molecule.

In yet another preferred embodiment, the peptide inhibitor comprises D-amino acids.

BRIEF DESCRIPTION OF THE DRAWINGS

20 **FIGURE 1.** Amino acid sequence of peptides A and E.

FIGURE 2. Structure of UL42/peptide A complex solved to a resolution of 2.7 Å.

25 **FIGURE 3.** A comparison of structure of processivity factors PCNA, gp45 and UL42.

FIGURE 4. Stereoviews of processivity factors PCNA, gp45 and UL42.

FIGURE 5. Concentration -response curves of peptide E mutant inhibition of long-chain DNA synthesis.
●-peptide E, O-R25A, ■-M27A, □-R30A

5 FIGURE 6. CD spectra of peptide E mutants.

FIGURE 7. Alignment of peptide display sequences with UL42.
●-peptide E, O-T20A, ■-E22A, □-R30A, Δ-H29A,
▲-F32A.

10

DETAILED DESCRIPTION

The instant invention encompasses the structure-based molecular design of inhibitors of processivity factor binding to proteins whose function is modified by
15 interruption of the binding interaction between the protein and processivity factor subunits. Although the disruption of specific protein-protein interactions is a promising strategy for drug development, the nature of these interactions can make such disruption impractical. Many protein-protein interactions involve large surfaces or multiple contacts, making it unlikely that a single small
20 molecule could interfere with them. In this regard, the instant inventors have identified particular binding sites in the polymerase/processivity factor interface.

“Processivity factor” as used herein is defined as a protein that modifies DNA polymerase to continuously incorporate many nucleotides using the same primer-template without dissociating from the template.

25 “Binding site” as used in the instant invention is any amino acid residue or residues of a protein, peptide or polypeptide which is involved in an attractive interaction with another residue or residues of a protein, peptide or polypeptide.

“Binding” as is used in the instant invention, refers to the attractive interaction between two or more molecules or between portions of two or more
30 molecules.

"Spider" as used herein denotes a specific peptidomimetic framework that mimics the vectors between the beta carbons of the i, i+4, i+5 and i+7 residues of an alpha helix

- In one aspect of the instant invention, there is provided, a method for
- 5 inhibiting processivity factor binding to protein. In overcoming the problems associated with the inhibition of protein-protein associations between DNA polymerase and processivity factors, the instant inventors have discovered particular and distinct binding sites on DNA polymerase and processivity factor.
- The particular binding sites are characterized as small and discrete to the degree
- 10 that interruptions or non-conservative mutations at these sites will cause effective inhibition of processivity factor binding and will effect, for example, inhibition of long chain DNA synthesis *in vitro*. Moreover, the instant inventors have surprisingly and unexpectedly discovered the structural and topographical uniformity of processivity factors to effect inhibition of processivity
- 15 factor/protein binding in for example, viral, bacterial, fungal and eukaryotic cells. Given these insights, such inhibition of processivity binding and inhibition of long chain DNA synthesis can be effected with an oligopeptide or a small molecule. The inhibitors can bind to sites on the polymerase or the processivity factor, or both.
- 20 The structure-based identification of relevant binding sites and inhibitors according to the instant invention involves: site-directed mutagenesis; peptide ligand display identification; structure-related studies of surrogate DNA polymerase C-terminus; Pol/UL42 crystal structure; homology modeling of processivity factors from other viruses and other organisms.
- 25 Mapping a protein-protein interaction identifies particular amino acids within potential binding sites for drug action. The instant invention is based, in part, upon the identification of binding sites on DNA polymerase and processivity factor comprising specific amino acids. These binding sites have been particularly targeted for the introduction of mutations into the respective
- 30 primary sequences. Comparative binding and DNA synthesis assays between the mutant polymerase and/or processivity factor and native/wild type proteins yield amino acid-specific data. These results particularly show potential binding sites.

Preferably, specific amino acid residues are pinpointed as sites for the introduction of mutations into the primary sequences. These amino acids are selected based upon their position such that if that amino acid residue position is modified, there will be a resultant alteration (i.e. decline) in the binding affinity.

5 Protein-protein interactions are often mediated by autonomous peptide motifs. By directing the assembly of specific protein complexes, such motifs can regulate diverse processes such as signal transduction, transcription and DNA replication. The present invention identifies specific binding sites within the C-terminal 36 residues of HSV polymerase (Pol), which are sufficient for
10 interacting with a processivity subunit. As mentioned *supra*, since this interaction is required for viral replication, it is a potential target for antiviral drug discovery.

For example, functional mapping of Pol has indicated that the C-terminal amino acid residues are indicated for processivity factor binding (Stow, N. D.
15 (1993) *Nucleic Acids Research* 21(1), 87-92; Digard et al., (1993) *J. Virol.* 67(1), 398-406; Marsden et al., (1994) *J. Gen. Virol.* 75(Pt 11), 3127-3135; Tenney et al., (1993) *J. Virol.* 67(1), 543-547). This region of Pol is not highly conserved among any other cellular DNA polymerase. A polypeptide corresponding to the C-terminal 36 amino acid residues of Pol, designated
20 Peptide A (FIGURE 1, Pol residues 1200-1235) selectively inhibits the ability of UL42 to stimulate long chain DNA synthesis (Digard et al., (1995) *Proc. Natl. Acad. Sci. USA* 92, 1456-1460). Peptide A and a fusion peptide comprising to the last 18 residues of Pol bind specifically to UL42 indicating that this region of Pol is sufficient for UL42 binding (Loregian et al., (1996) *Protein Expression and Purification* 8, 381-389). A shorter peptide corresponding to the last 18
25 residues of Pol, designated as Peptide E (FIGURE 1, Pol residues [1218-1235]) also binds UL42 and is a specific inhibitor of UL42 function (Digard et al., (1995) *Proc. Natl. Acad. Sci. USA* 92, 1456-1460).

Peptide E, which corresponds to the C-terminal helix of peptide A, acts
30 as a monomer and is only slightly less potent an inhibitor of long-chain DNA synthesis than peptide A. The binding of both peptides to UL42 as measured by isothermal titration calorimetry (ITC) correlates with their inhibitory activity,

suggesting that inhibition in the polymerase assay does reflect a direct interaction with UL42. Because the C-terminal 18 residues of Pol appear to be most important for this interaction, structure-activity studies were done with variants of peptide E. Taken together with mutagenesis studies, the segment 5 corresponding to residues 29-36 is a likely region for UL42 binding.

Surprisingly and unexpectedly, the region of Pol corresponding to peptide E is small and discrete, and therefore is a good target for site-directed mutagenesis studies. Mutations that most severely affected the inhibitory activity of this peptide occurred in two regions; at the N-terminus of the helix (T20A and 10 E22A) and in the extreme C-terminus of the molecule (H29A, R30A and F32A). In the case of T20A and E22A mutants, which had lower helix content than the other peptides based on ellipticity at 222 nm., the mutations may simply alter the overall structure of the peptide. In contrast mutations in the extreme C-terminus 15 of peptide E , including H29A and R30A had little effect on the degree of helicity, strongly suggesting that this region is directly involved in binding.

Mutational analyses of UL42 (~25 deletion mutants and ~22 four-codon linker insertion mutants) identified a single insertion mutation at codon 160 that specifically impairs Pol-UL42 binding without affecting DNA binding. Several additional mutations just upstream of codon 160 did not drastically impair the 20 Pol-UL42 interaction. However the closest insertion mutation downstream that we studied was at codon 191, leaving open the possibility that residues 160-190 include the subunit interface of UL42.

Mutagenesis is carried out using methods that are standard in the art, as described in, for example in *Current Protocols in Molecular Biology*, John Wiley 25 & Sons, Inc., 1998. The mutated or variant Pol or processivity factor sequence is cloned into a DNA expression vector and is expressed in a suitable cell such as, for example, *E. coli*. Preferably, the DNA encoding the desired sequence is linked to a transcription regulatory element, and the variant is expressed as part 30 of a fusion protein, for example, glutathione-S-transferase to facilitate purification. The variant protein is then purified using affinity chromatography or any other suitable method known in the art. "Purification" of polypeptide refers to the isolation of a protein or polypeptide in a form that allows its activity

to be measured without interference by other components of the cell in which the polypeptide is expressed.

Using known peptide display technologies, peptides are identified that bind specifically to the C-terminus of Pol. Peptide libraries developed from this methodology fall into more than one sequence class, each of which could serve as starting points for the discovery of new inhibitors. In particular, one class of peptides had a consensus sequence QxxPxV, (where Q is glutamine, P is proline V is valine and x is any amino acid), and site directed mutagenesis confirmed that the Q in the motif was required for binding. Homology with a segment of UL42 corresponding to the binding residues of processivity factor strongly suggests that this segment interacts with Pol. Through routine design procedures a peptide based on one of the peptide display sequences can be designed, and screened. This information is important for structure-based design since alternative sequence classes serve as a basis for the discovery of new inhibitory agents.

Protein display is carried out by methods common in the art. For example, phage display involves expression of proteins and peptides on the surface of filamentous phage. A library of randomly mutated peptide DNAs are ligated to a phagemid vector, for example, M13-based phagemid vector, so that mutant peptide is fused to the carboxy terminal domain of the phage protein. The carboxy terminus of the phage protein associates with the phage particle and the amino terminus, containing protein mutants, is displayed on the outer surface of the phage. The library of phagemids is introduced into *E. coli* and then *E. coli* are then infected with helper phage that induces the production of phagemid particles. The mutant peptide-phage complexes are passed over a column containing ligand covalently linked to a substrate (i.e. beads). Only the tight binding peptides are retained and non binding peptide-phage mutants pass through the column. The bound phage are isolated, cultured in *E. coli* and passed over the column again. Repeated rounds of selection result in the identification of peptide variants that bind ligand with exceptionally high affinity.

Molecular modeling and protein homology modeling techniques can provide an understanding of the structure and activity of a given protein. The structural model of a protein can be determined directly from experimental data

such as x-ray crystallography, indirectly by homology modeling or the like, or combinations thereof. Elucidation of the three-dimensional structure of the Pol-processivity factor complex provides a basis for the development of a rational drug design.

5 The structure of a complex of UL42 with peptide A has been solved to a resolution of 2.7 Å (FIGURE 2). The nature of the UL42-Pol interactions together with the above information immediately suggest structure-based strategies and *de novo* design of combinatorial libraries of potential antivirals against HSV. Initial design focuses on peptide and peptide-like ligands that will
10 compete with Pol for UL42 binding, or alternatively peptide or peptide-like ligands that compete with UL42 for Pol binding. The design focuses on specific interactions identified in the structure and particularly those interactions which were discovered by mutagenesis studies, e.g. Pol H1228 to UL42 R64 and Pol R1229 to UL42 Q171 (where H1228 and R1229 of Pol corresponds to H29 and
15 R30 of Peptide A). In general, a library of compounds is generated that are capable of binding to key binding sites.

A general design strategy exploits the similarities among protein-processivity factor interactions. The strategy begins with the UL42-peptide A interaction as a target. The first step is molecular design with a central region
20 capable of making extended interactions with the extended loop of UL42 and with additional groups at the end which bind to portions of the sites occupied by the terminal helices of peptide A. Alternatively, design libraries are made of molecules with a segment capable of making beta type interactions with the central portion of peptide A with additional functional groups to bind to specific
25 sites on the terminal helices. The design is amenable to any of a number of existing or even novel combinatorial chemistries known in the art that produce libraries of peptide-like small molecules.

Libraries are screened by standard assays, for example, inhibition of long chain DNA synthesis or screening the ability of molecules to displace an easily
30 detectable ligand from processivity factor or binding protein by, for example, radiolabeling or fluorescence labeling. The binding of screened compounds can be quantifiably characterized by isothermal calorimetry (ITC) which measures the

heat given off by the ligand protein interaction and permits assessment of K_d , stoichiometry, and changes in enthalpy and entropy upon binding (Ladbury et al., *Chemistry & Biol.* 3, 791-801). This assay is used to screen mutant forms and potential ligand libraries against native processivity factor or the polymerase 5 binding. Once a screened library is identified, it can be used as a structure-based “tool” for iterative modification and assay well within the skill of the artisan and the instant invention.

The instant invention encompasses the development of D-peptides useful for the inhibition of processivity factor binding to protein. This approach takes 10 advantage of mirror-image relationships between naturally occurring L-peptides and unnatural D-peptides (Schumacher et al., 1996 *Science* 271, 1854-1857). Once tight binders have been identified, screened and selected, peptides comprising D-amino acid versions of them are synthesized. These D-peptides should then be tight binders of the natural L-Peptide A and inhibit protein- 15 processivity factor interactions. As starting points for drug discovery, such peptides have a number of advantages over L-peptides, such as greater stability *in vivo*.

One route to drug discovery targeting the Pol-UL42 interaction is to identify peptides that mimic one interacting surface of the Pol-UL42 interaction 20 and then, by altering each residue, develop non-peptide inhibitors (peptidomimetics). These compounds are often smaller than the original peptide and able to enter cells and inhibit the enzyme *in situ*.


Alpha helices are a critical portion of many protein-protein, protein-nucleic acid interfaces, and small helical peptides have been demonstrated to be 25 capable of disrupting a number of macromolecular interactions. Therefore, small helical structures with appropriately chosen side chains might, in principle, serve as useful pharmacological agents. Unfortunately, with the exception of relatively small oligopeptides, the poor pharmacological properties of peptides (principally limited stability and limited ability to cross membranes) generally limit the utility 30 of peptides as drugs. This problem is compounded for peptides bound as helices, since the smallest known stable helices contain at least seventeen residues (Marqusee et al., PNAS 86, 5286-5290, 1989).

One embodiment of the present invention is a class of synthetically accessible peptidomimetic framework, called "Spiders", amenable to solid phase synthesis and combinatorial methods, to mimic the vectors between the beta carbons of the i , $i+4$, $i+5$ and $i+7$ residues of an alpha helix. The framework 5 displays four sidechains denoted R^1, R^2, R^3 , and R^4 . Charmm (Brooks et al., J. Comp. Chem. 4, 187-217, 1983; Karplus, M., CHARMM: Harvard College, 1992) calculations confirm that the minimum energy conformation of the Spider presents the sidechains in a position and orientation essentially equivalent to that of the four sidechains on one face of an alpha helix ($i, i+1, i+4, i+5$ or $i, i+3, 10 i+4, i+7$ sidechains). No conformational dependence on the identity of the particular sidechains has been found. Spiders are much smaller than a comparable helix, which are believed to make them superior drug candidates, and they have fewer degrees of backbone freedom (5 vs. 16 for a typical helix) which is believed to reduce the energy penalty for binding.

15 Any biologically or pharmacologically relevant helix could be replaced by a corresponding Spider, making such Spiders attractive lead candidates for drug design and for target validation.

An illustrative synthetic scheme for preparing a Spider is shown below. Sidechains may correspond to the side chains of natural or unnatural amino acids. 20 The stereochemistry of the R^1 and R^4 side chains could correspond to a D or an L amino acid, or (in the case of multiple stereo-centers) to any other stereochemistry. Combinatorial approaches (either split-and-pool synthesis or parallel synthesis) may be used to determine optimum sidechains. The Spiders have fewer degrees of freedom (5 in Spider backbone, vs. 16 for backbone of 25 eight-residue helix). Consequently, entropy effects should favor the binding of Spiders over that of helices.

Solid phase synthesis of Spiders




5


Three illustrative Spiders are shown, whose synthesis is achieved using standard methods, with the following sequences: EHNQ, WDHQ and RDHO, where the ⁿth letter is the 1-letter amino acid code for the side chain or side chain fragment attached to position R_n of the Spider, (O stands for anthracine).

- 10 All three spiders were selected in part using information provided by MCSS (Evensen et al., MCSS version 2.1, Cambridge, MA: Harvard University, 1997) calculations carried out on UL42 and mutagenesis experiments performed on Pol. The design protocol is given below. Each of the three spiders was designed to interact with UL42 and to sterically conflict with Pol, thus preventing it from
- 15 binding to UL42.

Spider EHNQ



Spider WDHQ




Charmm calculations (Brooks et al., J. Comp. Chem. 4, 187-217, 1983;

- 5 Karplus, M., CHARMM: Harvard College, 1992) indicate that the interactions formed by Spider EHNQ are primarily between polar or charged residues. The Glu (E) forms a salt-bridge with Arg 35 of UL42, (and can be closely superimposed on residue D1232 of the polymerase peptide). The His (H) is positioned between Asp 34 and Arg 35, and interacts electrostatically with both.
- 10 The positive region of the Asn (N) forms a polar interaction with Asp 34. The Gln (Q) interacts with Arg 35 and His 54 of UL42.

The second Spider, WDHQ, was designed to interact with a hydrophobic region on the "floor" of the groove in which the peptide binds, which consists of Phe 49, Pro 51, Leu 52, Val 138, Pro 141, Ala 262, and Val 266, together with the backbones of other residues. The WDHQ Spider was the best of several Spiders that have both hydrophobic residues designed to interact with the floor of the groove and hydrophilic residues to interact with nearby hydrophilic target residues. Charmm calculations (Brooks et al., J. Comp. Chem. 4, 187-217,

1983; Karplus, M., CHARMM: Harvard College, 1992) indicate that the Trp (W) interacts with Pro 51 and Leu 52. The Asp (D) forms a salt bridge to Arg 35, and the H is located in between Arg 35 and Glu 53, interacting with both. The Gln (Q) does not interact with UL42, but attempts to replace it with residues 5 that do were not successful.




10

The Spider RDHO, with the O standing for anthracine, interacts with both the floor of the groove and with hydrophilic residues, and its design is similar to that of WDHQ. Charmm calculations (Brooks et al., J. Comp. Chem. 4, 187-217, 1983; Karplus, M., CHARMM: Harvard College, 1992) indicate that the 15 anthracine forms hydrophobic contacts with Phe 49, Pro 51 and Pro 141 (which is along the side of the groove). The D forms a salt bridge with Lys 243, and the H makes the same interactions as the H in Spider WDHQ. The Arg (R) does not specifically interact with any residue in UL42.

Although the above synthesis depicts a serial synthesis in which the 20 central 1-amino-4-carboxycyclohexane moiety is constructed on a growing peptide chain, it will be appreciated that libraries may be assembled in which the 2,5-disubstituted-1-amino-4-carboxycyclohexane units are synthesized separately

and treated as pseudopeptide monomers in standard automated peptide synthesis. Multiple 2,5-disubstituted-1-amino-4-carboxycyclohexanes may also be coupled sequentially. This can mimic a larger helix. Combinatorial approaches can also be used on such larger molecules. A few illustrative Spiders with larger
5 structures are shown below.



It will be apparent to the ordinary skilled artisan that many other variants are possible that also provide the required stereochemical relationship of amino acid side chain fragments to mimic both helical and non-helical portions of either the polymerase or the processivity factor component of a complementary pair 5 necessary for DNA expression or repair. In the above illustration for peptidomimetics of helical structures, it will be apparent that the cyclohexane rings can be replaced by other homocyclic or heterocyclic alicyclic or aromatic rings of various sizes and shapes, including fused and bridged ring systems. By the same token, the linkage between rings can be direct, or through intermediate 10 linker moieties, including those comprising peptide bonds to facilitate solid phase synthesis. Existing combinatorial chemical techniques can be used to select appropriate rigid scaffolds to achieve the spatial and conformational orientation of functional groups to interact with groups on the polymerase or processivity factor and inhibit binding of the two complementary proteins. It will be 15 appreciated also that amino acid side chain functional groups can be replaced by analogues having similar functionality, e.g., sulfonate, phosphate for carboxylate; sulphydryl for hydroxyl; urea, carbamate, urethane for guanidine; and the like. Several atoms in a side chain can be incorporated into rings or other mimetic fragments in a similar fashion to the illustrated groups above. In 20 appropriate cases, this provides further rigidity and fewer degrees of freedom to the system.

Computational methods

There are many successful techniques for determining the optimum binding position and orientation for a small molecule of known structure (the 25 "docking problem"). Techniques also exist for determining the optimum sidechains. These include dead-end elimination of a molecule with a particular binding conformation. See, e.g., Dahiyat et al., Protein Sci 6, 1333-7, 1997; Lasters et al., Protein Eng 6, 717-22, 1993. The present inventors use a novel methodology to determine optimum sidechains for their peptidomimetic scaffold 30 along with its optimum position and orientation.

The distribution of conformations of macromolecules in equilibrium constitutes a canonical ensemble. In this state, the lowest energy minima will be

the most populated, and larger energy gaps will lead to a larger portion of the population being similar to the lowest energy conformation. Conversely, the distribution of conformations themselves can be used to determine the energy gap of a molecule. Studies, e.g., DeWitte et al., JACS 118, 11733-11744, 1996; 5 Finkelstein et al., 1993). FEBS 325, 23-28, 1993, have argued that the principles of canonical statistical mechanics can be applied to subsets of folded proteins because the subsets are in thermal equilibrium with each other. For similar reasons, the present inventors have found that the principles of canonical statistical mechanics can be applied to ligand sidechains, provided that the ligand 10 remains bound to its target significantly longer than the time scales of the thermal fluctuations of the system.

Multiple (typically 150) simulated annealing dynamics calculations, each using a different random number seed, are carried out using Charmm (Brooks et al., 1983; Karplus, 1992). Sidechains that have a small positional variance are 15 likely to be making large energetic contributions to binding, while those with a large positional variance are less likely to be making energy contributions to binding. The sidechain with the greatest positional variance is changed to another sidechain; the replacement sidechain is selected on the basis of stereochemical intuition, Monte-Carlo criteria or other methods. The entire 20 process is repeated until convergence is achieved.

It is necessary to resort to indirect measurement of the energy contributions of sidechains because binding is often largely driven by enhanced intra-molecular binding due to solvent screening, and so direct measurement of sidechain energy contributions is often difficult or misleading. See, e.g., 25 Hendsch et al., Protein Science 8, 1381-1392, 1999.

Based upon the structure of peptide and non-peptide lead compounds, it is well within the skill of the ordinary artisan to develop non-peptide small molecule inhibitors for example, with the use of a computer to put different functional groups together yielding small molecules that bind tightly. The success 30 of a structure-based drug design method is then enhanced through the use of advanced methods of computation. These methods expedite the identification of key molecular fragments which then are joined to form larger fragment

molecules (LUDI: Bohm, H.J. (1992) *J. Comput. Aid. Mol Des.* 6: 61-78; MCSS: Miranker, A. and Karplus, M. (1991) *Proteins* 11: 29-34; GRID: Goodford, P.J. (1985) *J. Med. Chem* 28:849-85) or whole molecules either from a database of existing compounds or through a molecular growth algorithm 5 (DOCK Kuntz et al., 1992 *Science* 257, 1078-1082; Kuntz et al., 1982 *J. Mol. Biol.* 161, 269-288). These computational advances enhance the ability to develop molecules or ligands which will successfully bind to protein sites. An iterative cycle is conducted of solving structures of new compounds and assay, permitting the design of better candidate inhibitors. Compounds which bind are 10 rescreened for ability to inhibit a biochemical process (e.g., processive DNA synthesis in vitro) or biological process (e.g., virus replication in vivo) to identify viable drug candidates.

There is provided, in one aspect of the invention, methods for treating infections effected by viruses, bacteria, and fungi. Despite the disparate 15 mechanisms and lack of sequence homology, UL42 bears a striking structural homology with other sliding clamps as shown in FIGURE 3. Stereoviews of processivity factors in FIGURE 4 also show a common topology. Moreover, the nature of the UL42-Peptide A interaction bears a striking similarity with the interaction of processivity factor RB69 gp45 with a RB69 Pol-derived peptide 20 and the interaction of human processivity factor PCNA with a peptide derived from cell cycle regulator, p21. In the UL42-Peptide A complex and the PCNA-p21 peptide complex, the peptides form a short stretch of beta interactions with a portion of a loop that connects the bottom half and top half of the processivity factor. In all cases the peptides bury an aromatic side chain in a conserved 25 hydrophobic pocket near the carboxy terminal end of the connecting loop in the processivity factor. The crystal structure of the UL42-Peptide A complex does in fact indicate that specific contacts are made between UL42 and the C-terminal helix of Peptide A, including one with the side chain of arginine 30 (which corresponds to R1229 in the intact polymerase).

30 To go from the specific case of UL42-Pol interactions to other targets, use is made of the similarities between the UL42-peptide A structure and the sliding clamp-peptide structures. As shown in FIGURES 2 and 3, the structure of

processivity factor PCNA has been solved alone and as a complex with a peptide fragment from the regulatory protein p21. The p21 peptide interacts with a face of the PCNA molecule that can be thought of as a twisted surface comprised of beta sheets which is crossed by a long extended stretch of residues called the connecting loop. The structure, of a second clamp-like processivity factor, the gp45 protein from the phage RB69 has been solved alone and in complex with a peptide corresponding to the extreme C-terminus of the phage polymerase. The structure of the gp45 trimer is strikingly similar to the PCNA clamp (FIGURE 4). The C-terminal peptide from the phage polymerase interacts with a face of the gp45 protein that is homologous to the p21 binding face in PCNA. However, there have been no reported studies done of particular binding sites important for binding between gp45 and phage polymerase.

The strong similarities between the interactions in the known processivity factor peptide complexes puts it well within the skill of the artisan that this structure-based strategy may be quite general for other polymerases including bacterial, fungal and eukaryotic polymerases. Indeed, it is not necessary to solve the structure of a new processivity factor or peptide-processivity factor complex in order to derive a template for combinatorial libraries. Instead it is sufficient to derive a structure-based sequence alignment and a profile that allows the sequence of a processivity factor of unknown structure to be threaded into the framework of the known structure. These provide sufficient information to establish combinatorial libraries *supra*. This approach is quite general, allowing the design of inhibitors of processivity factor-Pol interactions for any polymerase which are candidate antivirals against a number of DNA viruses (e.g. herpesviruses, poxviruses), and the design of antimicrobials against pathogenic bacteria, pathogenic protozoans, and pathogenic fungi. Additionally, given the interactions of PCNA with a cell cycle regulatory protein and the interactions of repair proteins similar to sliding clamps with other proteins, this approach will be useful in cancer chemotherapy.

Although, the instant invention is drawn to the inhibition of interactions between processivity factor and protein in general, particular proteins are known to have functional modification or change effected by processivity factor binding,

for example, restriction repair enzymes or cell cycle regulators. As such, other proteins that interact with processivity factors are within the knowledge of one of ordinary skill and therefore, well within the scope of the instant invention.

Because there are recognizable sequence homologies between UL42 and the processivity factors of the alpha herpesviruses (e.g., HSV-1, HSV-2, Varicella zoster virus and pseudorabies virus), the derivation of homology models for the processivity factors of the alpha-herpes viruses will be straightforward. Similarly, significant sequence homologies among eukaryotic PCNA's should allow relatively straightforward derivation of homology models for the eukaryotic processivity factors. Protein homology modeling requires the alignment of the protein under study with a second protein whose crystal structure is known. Information gained from these structure sequence alignments together with structure alignments of the processivity factors that have experimentally derived structures are used to derive a profile that will allow homology modeling and even identification of other processivity factors and target binding sites.

For example, a standard method for structure-based modeling adapted to this invention comprises modeling a target processivity factor based on a template selected from experimentally derived processivity factor structures, wherein the modeling comprises:(i) aligning the primary sequence of the target processivity factor sequence on the sequence of the template by pair-wise, structure-based or multiple sequence alignment to achieve a maximal homology score followed by repositioning gaps to conserve regular secondary structures; (ii) transposing the aligned sequence to the three dimensional structure of the template to derive the three-dimensional structure of the target processivity factor; (iii) subjecting the structure obtained in step (ii) to energy minimization; and (iv) identifying binding sites in the model based upon corresponding binding sites from the experimentally derived processivity factor structures.

Where standard sequence alignment tools fail to recognize sequence homologies between UL42 and other known non-herpes processivity factors (including the processivity factors of the beta and gamma herpesviruses), secondary structure-based predictions to match proteins are able to detect a

significant relationship between UL42 and known processivity factor structures.

In this regard, it is useful to note that, whereas standard sequence alignment tools fail to recognize sequence homologies between UL42 and other known non-herpes processivity factors, computer-based tools that use secondary structure

5 predictions to match proteins, for example, (<http://fold.doe-mbi.ucla.edu/Home>) was able to detect a significant relationship between UL42 and PCNA.

As such, a structure-based method for designing potential inhibitors of a DNA polymerase comprises modeling a target processivity factor based on a template selected from experimentally derived processivity factor structures, 10 wherein said modeling comprises: using computer-based tools predicting secondary structure in said target based upon secondary structure in said template to provide a three dimensional model of said target; and identifying binding sites in said model based upon corresponding binding sites from said template.

Inclusion of the structures of all four processivity factors whose structures 15 are known (PCNA, the *E. coli* β subunit, gp45 and UL42) and the sequences of all known members of each of the families represented by the three structures, enables one of ordinary skill to significantly expand the ability to generate homology based structures and structure-based inhibitors of processivity binding to other polymerases, for example, eukaryotic, fungal and bacterial.

20 In another aspect of the instant invention, there are provided methods for treating cancer or inhibiting tumor growth. Cancer, as is used in the instant invention, refers to any abnormal new growths of tissue. There are two ways in which the instant invention can lead to therapies for treating cancer. Cancer cells are usually characterized by having fewer controls on the replication of their 25 DNA than do normal cells. Thus, inhibition of DNA synthesis is well established as a mechanism for selectively inhibiting tumor cells. Inhibiting the interactions between cellular DNA polymerases such as DNA polymerase delta with their processivity factors, e.g. PCNA, is one approach to inhibit tumor cell replication. A second strategy would be to block the interaction of p21 or other 30 regulatory proteins with PCNA or other processivity factors. In the absence of other regulatory pathways, which would be more likely to be missing in cancer cells than in other cells, this approach drives cancer cells into unscheduled DNA

replication, leading to cell death, perhaps in combination with other agents that would, for example, be incorporated into replicating DNA. Once compounds are screened for inhibitory activity as described, assays are carried out for anti-cancer activity such as tumor cell death *in vitro*, or by measuring, for example, 5 tumor growth or tumor weight *in vivo* in a suitable model such as a rat or mouse.

Based on the description *supra* it will readily be appreciated by those of ordinary skill in the art that the instant invention can be used for design of agents that block interaction of HSV Pol and UL42 as antivirals against HSV-1 and 10 HSV-2 and the design of agents that block Pol/processivity factor interactions in other alphaherpes viruses that cause disease in humans including varicella zoster, and monkey herpesvirus B as antivirals.

The instant invention can also be used for the particular design of agents that block Pol/processivity factor interactions in other human herpes viruses 15 including the beta herpes viruses such as CMV, HHV6 and HHV7 and the gamma herpes viruses such as Epstein-Barr Virus and HHV8 as antivirals.

The instant invention can also be used for the particular design of agents that block Pol/processivity factor interactions in beta- herpesviruses that cause viral infection in animals e.g. pseudorabies virus, equine herpesviruses, bovine 20 herpesviruses as veterinary antivirals, design of agents that block polymerase/processivity factors in any other DNA virus that encodes its own polymerase and processivity factor (e.g. variola) as antivirals, design of agents that block Pol/processivity factors of pathogenic bacteria as specific antibacterials, design of agents that block Pol/processivity factor interactions in 25 pathogenic fungi as antifungals, design of agents that block Pol/processivity factor interactions in pathogenic protozoans as antiprotozoans, design of agents that block processivity factor-protein interactions in cancer cells as anti-tumor drugs or drugs that potentiate the action of other anti-tumor drugs.

The present invention, thus generally described, will be understood more 30 readily by reference to the following examples, which are provided by way of illustration and are not intended to be limiting of the present invention.

Materials

Peptide A and its variants were synthesized as described previously (Digard et al., 1995 *Proc. Natl. Acad. Sci. USA* 92, 1456-1460). Alanine scan mutants of peptide E. HSV Pol and UL42 were purified from insect cells 5 infected with the appropriate recombinant baculoviruses as described previously(Gottlieb et al., 1990 *J. Virol.* 64, 5976-5987; Marcy et al., 1990 *Nucleic Acids Res.* 18(5), 1207-1215. Poly(dA) template and oligo(dT) primer were purchased from Pharmacia. TTP (thymidine triphosphate) was purchased from Boehringer Mannheim and [³²P]-TTP was obtained from DuPont NEN.

10

Site-directed mutagenesis mapping on peptide E

To address the contributions of various residues to the interaction, peptides were synthesized in which each of the non-alanine residues in peptide E was substituted with alanine (Ala) to try to maintain helicity, but change 15 sequence. These peptides were tested for their effects on UL42-mediated long chain synthesis. TABLE 1 indicates two clusters of substitutions that eliminated detectable inhibitor activity; one cluster near the N-terminus of the peptide and the other near the C-terminus (the M27A mutant inhibited long chain synthesis by about 40% at 100 μ M). The N-terminal substitutions reduced helicity as 20 measured by ellipticity at 222 nm.

TABLE 1 also shows that protein-protein mapping indicates residues in the C-terminus such as H29, R30 and F32 may be indicated for the interaction with UL42 and indeed may directly participate in this interaction. This also 25 indicates that a small molecule could also exert drastic effects on the Pol-UL42 interaction at these sites.

30

Peptide	IC ₅₀ (μ M)	% Helicity
A	1.7 \pm 1	20
E	11 \pm 5	25
T20A	> 100	16
E22A	> 100	14
E23A	21 \pm 8	
T24A	77 \pm 30	
R25A	40 \pm 13	
R26A	14 \pm 9	
M27A	> 100	
L28A	18 \pm 6	
H29A	> 100	25
R30A	> 100	26
F32A	> 100	28
D33A	50 \pm 13	
T34A	10 \pm 5	
L35A	97 \pm 5	

Table 1. Inhibition of long chain DNA synthesis by peptide E mutants. The IC₅₀ values (concentrations of peptides that give 50% inhibition) \pm standard deviation of the various peptide E mutants and the % helicity calculated from ellipticity values at 222 nm from CD measurements. Assays performed essentially as described (Digard et al., 1995). The mutants are named relative to the peptide A sequence with the first letter and number = wt residue number; A = alanine.

Identification of specific residues of peptide E for inhibitory activity

To perform structure-activity studies, "alanine scan" mutants of peptide E, in which each non-alanine residue was individually converted to an alanine, were synthesized and tested for their ability to inhibit long-chain DNA synthesis by Pol and UL42. A poly(dA)/oligo(dT₁₅) template/primer was employed. On this primer/template, Pol alone adds only one or two bases, but when UL42 is present, longer DNA products are formed. DNA products greater than 18 bases were quantified at varying peptide concentrations and expressed as a percentage of products formed by Pol/UL42 in the presence of vehicle control. These values were used to generate concentration-response curves, examples of which are shown in FIGURE 5. As summarized in TABLE 1, mutants E23A, R26A, L28A and T34A, numbered relative to the peptide A sequence, had activities similar to that of peptide E. Mutants T24A, R25A and D33A were only moderately impaired in their ability to inhibit processivity with IC₅₀ values 3 to 7-fold greater than that of peptide E. Mutants L35A and M27A had even less activity exhibiting 50% and 40% inhibition at 100 μ M respectively (data not shown). The most impaired mutants were T20A, E22A, H29A, R30A and F32A, which exhibited less than 20% inhibition at 100 μ M. None of the peptide mutants inhibited Pol

catalytic activity in the absence of UL42, demonstrating their specificity for UL42-mediated DNA synthesis.

CD spectroscopy was performed in order to determine if the peptides with the least inhibitory activity were altered structurally. As shown in FIGURE 6, 5 wavelength scans of the mutants were characteristic of helical peptides with minima at 222 and 205 nm and a maximum at 190. Mutants T20A and E22A had substantially lower ellipticity at 222 nm than the other peptides, suggesting a loss of helical content. Therefore, the lack of inhibitory activity of these two mutants may be at least in part due to alterations in structure. Although the 10 mutant F32A had a minimum at 222 nm similar to that of peptide E, it had a much deeper minimum at 205 nm, perhaps signifying a loss of helicity in this peptide as well. The CD spectra of the H29A and R30A mutants were nearly indistinguishable from that of peptide E suggesting that these residues may be directly involved in binding.

15

CD Spectroscopy

Lyophilized peptides were resuspended in 10 mM KF and adjusted to pH 8 with KOH. Spectra were recorded at the indicated peptide concentrations with an Aviv 62DS SpectroPolarimeter at 0°C in a 0.1 cm pathlength cuvette. 20 Wavelength scans were recorded at 1 nm intervals with a 5 second averaging time, and 5 to 10 scans were averaged. Peptide concentrations were determined by quantitative amino acid analysis. Unfolding curves were obtained by monitoring mean residue ellipticity at 222 nm as a function of the concentration of guanidine-HCl and temperature. These experiments employed an automated 25 titrator as suggested by the vendor.

Site-directed mutagenesis mapping on UL42

Mutant maltose binding protein (MBP)-UL42 fusion proteins were constructed with alterations in the consensus residues identified by peptide 30 display. For example, glutamine 171 was altered. The mutant protein did not support long chain synthesis by Pol. It did not interact with peptide A in ITC assays, although it retained the ability to bind DNA. Thus, this segment of

UL42 is specifically crucial for Pol binding. This supports the idea that this segment forms at least part of the Pol-binding site, which will provide a starting point for finding peptides and eventually peptidomimetics that can bind to Pol and inhibit viral replication. It also can abet structure-based design.

5

Peptide Display Identification of Ligands

Peptide ligands that could bind to GST-peptide A, but not to GST alone were selected, using phage display and *E. coli* flagellar display (valencies of 5-10 peptides), eluting bound ligands with UL42 or NaCl. A number of classes of 10 peptides were identified. Each of these classes could serve as a starting point for drug discovery. Both display methods selected peptide sequences that align with the region of UL42 downstream of residue 160, specifically residues 171-176 (FIGURE 7). This indicates that residues 171-176 form at least a portion of the Pol-binding site on UL42.

15

Polymerase Assays

Reaction mixtures contained 50 mM Tris-Cl (pH 7.6), 100 mM (NH₄)₂SO₄, 3 mM MgCl₂, 0.1 mM EDTA, 1 mM dithiothreitol, 0.1 µg BSA, 4% glycerol, 0.25 µg of poly(dA)-oligo(dT) primer/template, 50µM [³²P] -TTP (5 Ci/mMol), 100 fmol of HSV Pol, 200 fmol of UL42 and varying concentrations of peptide inhibitors in a final volume of 25 µL. Reactions were carried out at 20 37°C for 5 to 10 minutes. Reactions were stopped by placing them on ice and adding 5 µL of alkaline loading buffer (2 mM EDTA, 50 mM NaOH, 2.5 % glycerol, 0.025 % bromcresol green) and were then loaded onto a 4% alkaline 25 agarose gel. Gels were dried overnight and used to expose film and phosphorescence screens. Because Pol alone added only 1-2 nucleotides to the 15 base primer, newly synthesized DNA larger than 18 bases was defined as long-chain and quantified using a Molecular Dynamics Phosphorimager.

30

Pol/UL42 Crystal StructureProtein purification

UL42ΔC320 (a construct truncated at residue 320 to delete a proline-rich domain) was expressed as a fusion protein to maltose binding protein (MBP), and Peptide A was expressed as a fusion protein to glutathione-S-transferase (GST). Both proteins contained a PRESCISSION™ protease site between the protein of interest and the fusion partner. The proteins were expressed in *E. coli* strain BL21(DE3)pLysS. Typically 8 liters of cells (6L of MBPUL42ΔC320 and 2L of GSTpeptideA) were grown in LB media containing 2% glucose and 100µg/mL of ampicillin. The cells were grown to an O.D. 600nm of between 0.6-0.8, and then induced for 5 hours by the addition of 3mL of 100mM IPTG. The cells containing each protein were combined and pelleted at 3000xg. The pelleted cells were resuspended in 50mM TRIS pH 7.5, 500mM NaCl, 10mM EDTA, 2mM dithiothreitol (DTT) and 1% Triton X-100, and stored at -20°C until needed.

The cells were thawed and lysed by sonication. The lysate was centrifuged at 10,000xg for 20 minutes and applied to a 10mL glutathione Sepharose column that had been equilibrated with 50mM TRIS pH 7.5, 500mM NaCl, 5mM EDTA, and 2mM DTT. The column was washed with approximately 50mL of equilibration buffer, followed by a wash with 50mM TRIS pH 7.5, 150mM NaCl, 5mM EDTA and 2mM DTT until the absorbance at 280nM had returned to baseline. The bound proteins were eluted off the column with 100mM TRIS pH 7.5, 150mM NaCl, 5mM EDTA, 2mM DTT and 15mM reduced glutathione. The fractions containing the protein as judged by the UV absorbance at 280nm, were pooled and PRESCISSON™ protease was added. The sample was dialyzed overnight against 50mM TRIS pH 7.5, 150mM NaCl, and 2mM DTT. The sample was next desalted in a Centriprep 10 (Millipore) concentrator using a buffer of 50mM HEPES pH 7.5, 2mM DTT. The desalted mixture was applied to a single stranded DNA agarose column that had been equilibrated in 50mM HEPES pH 7.5, 2mM DTT. The bound protein was washed with 50mL of 50mM HEPES pH 7.5, 100mM NaCl and 2mM DTT.

The bound complex of UL42 Δ C320/peptide A was eluted off the column using 50mM HEPES pH 7.5, 2mM DTT and 750mM NaCl. The protein was then desalted in a Centriprep 10 concentrator using 50mM TRIS pH 8.5, 2mM DTT. The desalted protein was applied to a 5mL Fast Q-Sepharose column equilibrated 5 with 50mM TRIS pH 8.5, 2mM DTT. The protein was eluted off using a linear salt gradient from 50 to 600mM NaCl. The purified complex was then dialyzed overnight against 50mM TRIS pH 7.5, 150mM NaCl, 2mM DTT.

Preparation of Selenomethione UL42 Δ C320/Peptide A

10 Selenomethionine UL42 Δ C320 was prepared by the overexpression of the protein in *E. coli* strain BL21(DE3)pLysS in M9 minimal media containing 2% glucose and 100 μ g/mL of ampicillin. Once cells reached an O.D. at 600nm of 0.8-1.0 methionine biosynthesis was down regulated by the addition of isoleucine, leucine, lysine, phenylalanine, threonine, and valine. Fifteen minutes 15 after the addition of the supplemental amino acids, the cells were induced for 5 hours by the addition of 3mL of 100mM IPTG. Cells were pelleted at 3000xg and resuspended in 50mM TRIS pH 7.5, 500mM NaCl, 10mM EDTA, 2mM dithiothreitol (DTT) and 1% Triton X-100, and stored at -20°C until needed.

Subsequently the cells were thawed and combined with cells containing 20 GST-Peptide A that were grown as described in the above section. The combined cells were lysed, and the complex purified as described above.

Crystallization

The purified protein was concentrated to 7-10mg/mL as judged by 25 Bradford assay. The concentrated protein was crystallized by the vapor diffusion method using 14-10% polyethylene glycol monomethyl ether 5000 as the precipitant. 2 μ l of complex were mixed with 2 μ l of reservoir solution on a siliconized coverslip and then inverted over the reservoir solution. Crystals usually appeared within 1-3 days. Crystals belonged to spacegroup P2₁ with unit 30 cell dimensions a=54.3 b=100.6 c=129.5 \AA and $\beta=100.6^\circ$. There are four molecules of the UL42/Peptide A complex in the asymmetric unit. The native

Patterson gave a strong peak at approximately 1/2, 0, 1/2 suggesting a pseudocentering operation.

The coverslips containing the crystals were inverted and cryosolvent (reservoir solution containing 20% glycerol, 25mM TRIS pH 7.5, and 125mM NaCl) was added until no further mixing was observed. The crystals were mounted in nylon loops and frozen directly in the nitrogen stream. Crystals used at CHESS (Cornell High Energy Synchrotron Source) were stored in liquid nitrogen until the time of data collection.

Heavy atom derivatives were made by soaking the crystals in reservoir solution contain 1mM of the heavy atom compound either ethylmercury phosphate (EMP) or trimethyl lead acetate (TMLA) for between 12 and 24 hours, and mounted in nylon loops as stated above.

Data from all the crystals were processed using DENZO and SCALEPACK (Otwinowski, 1993, Data Collection and Processing, L. Sawyer, N. Isaacs and S. Bailey, eds. (SERC Daresbury Laboratory, Warrington, pp. 56-62). Structure factors from both data sets were calculated using TRUNCATE, and the derivative, native and selenomethionine data sets were scaled using SCALEIT (CCP4, Bailey, 1994, Acta Cryst. D50, 760-763).

20 Structure Determination

The positions of the lead and mercury sites were determined using conventional Patterson methods and difference Fouriers. The selenomethionine sites were found using anomalous difference Fouriers using the combined phases from the mercury and lead derivatives. The position of the heavy atom sites were refined using SHARP (Fortelle et al., 1997, SHARP: A maximum likelihood heavy-atom parameter refinement and phasing program for the MIR and MAD methods, Volume 7, P. Bourne and K. Watenpaugh, eds.) and initial MIRAS (multiple isomorphous replacement with anomalous scattering) phases were calculated. The data was then subjected to solvent flipping using SOLOMON (Abrahams and Leslie, 1996, Acta. Cryst. D52, 30-42). The position of the heavy atom sites allowed the definition of the noncrystallographic symmetry (NCS) operators. Four fold NCS averaging greatly improved the

quality of the experimental phases and allowed the initial tracing of the chain using the program O (Jones et al., 1990, *Acta Cryst. A*47, 110-119).

The structure was refined using CNSv0.5 (Brünger, 1992, *A System for X-ray Crystallography and NMR*, New Haven: Yale University Press); Brünger et al., 1998, *Acta Cryst. D*54, 905-921). Rounds of energy minimization, followed by simulated annealing and B-factor refinement were carried out with rebuilding of the structure using O between cycles of refinement. NCS restraints were used between pairs of molecules related by the pseudotranslational symmetry. The working and free R value for the current model for all data to 2.7Å resolution are 10 0.23 and 0.28 respectively and the rms deviations from ideal bond lengths and angles are 0.015Å and 2.1° respectively.

The invention has been disclosed broadly and illustrated in reference to representative embodiments described above. Those skilled in the art will 15 recognize that various modifications can be made to the present invention without departing from the spirit and scope thereof.

WE CLAIM:

1. A method for obtaining inhibitors of processivity factor-mediated protein function, comprising:

(a) identifying binding sites on a protein, or a portion thereof, wherein said protein's function is modified by the binding of a processivity factor, or binding sites on said processivity factor that binds to said protein;

(b) targeting as a site for inhibition, at least one binding site, based upon the identification made in (a);

(c) identifying a library of compounds that are capable of binding to said at least one binding site; and

(d) screening said library to identify inhibitors of binding of said protein to said processivity factor.

2. The method of claim 1, wherein said protein is a DNA polymerase, a DNA repair enzyme or a portion thereof.

3. The method of claim 1, wherein said processivity factor is HSV UL42, *E. coli* β -subunit of DNA polymerase III, bacteriophage T4 or RB69 gp45.

4. The method of claim 2, wherein said protein is herpes simplex virus (HSV) DNA polymerase, or the Peptide-A or Peptide-E portion thereof, and said processivity factor is HSV UL42.

5. A structure-based method for identifying and selecting inhibitors of a DNA polymerase, comprising:

(a) modeling a target processivity factor based on a template selected from experimentally derived processivity factor structures, wherein said modeling comprises: (i) aligning the primary sequence of said target processivity factor sequence on the sequence of said template by pair-wise, structure-based or multiple sequence alignment to achieve a maximal homology score, followed by

repositioning gaps to conserve regular secondary structures; (ii) transposing said aligned sequence to the three dimensional structure of said template to derive the three-dimensional structure of said target processivity factor; (iii) subjecting the structure obtained in step (ii) to energy minimization; and (iv) identifying binding sites in said model based upon corresponding binding sites from said experimentally derived processivity factor structures;

(b) targeting as a site for inhibition, at least one amino acid in at least one of said binding sites, based upon the identification made in (a);

(c) identifying a library of compounds that are capable of binding to said at least one binding site; and

(d) screening said library to identify inhibitors of said DNA polymerase.

6. A structure-based method for identifying and selecting potential inhibitors of a DNA polymerase, comprising:


(a) modeling a target processivity factor based on a template selected from experimentally derived processivity factor structures, wherein said modeling comprises: using computer-based tools predicting secondary structure in said target based upon secondary structure in said template to provide a three dimensional model of said target; and identifying binding sites in said model based upon corresponding binding sites from said template;

(b) targeting as a site for inhibition, at least one amino acid in at least one of said binding sites, based upon the identification made in (a);


(c) identifying a library of compounds that are capable of binding to said at least one binding site; and

(d) screening said library to identify inhibitors of said binding sites.

7. An inhibitor obtainable using the method of any one of claims 1-6, which is a peptidomimetic having a structure selected from the group consisting of




and




wherein each R group represents H or the portion of the side chain of a natural or unnatural amino acid starting at the gamma carbon.


8. The peptidomimetic of claim 8 having the structure



9. The peptidomimetic of claim 9 having a structure selected from the group consisting of




Spider EHNQ



and

Spider WDHQ



10. A method for treating an infection mediated by a virus, bacterium, protozoan or fungus, comprising administering to an infected animal an effective therapeutic amount of an inhibitor of a DNA polymerase of said virus, bacterium, protozoan or fungus, wherein said inhibitor is obtainable by the method of any one of claims 1-6.

11. The method of claim 10, wherein said infection is a viral infection.

12. The method of claim 11, wherein said virus is HSV.

13. The method of claim 11 or 12, wherein said inhibitor is a peptidomimetic of any one of claims 7-9.

14. A method for treating cancer, comprising administering to an animal suffering from cancer a therapeutic amount of an inhibitor of tumor cell DNA polymerase, wherein said inhibitor is obtainable by the method of any one of claims 1-6.

1 Ac-DVAA¹⁹RLRAAGFFGAVGAGATAEETR³⁶MLHRAFDTLA
 1200 1218 Peptide A
 1235 Pol Residues
 Ac-
 -NH₂ Peptide E

Figure 1. Amino acid sequence of peptides A and E.

Fig 2





Fig 3

PCNA



gp45





UL42



Fig 4



gp45



PCNA



UL42



Fig 5





Fig 6



7 / 7

H	A	C	N	<u>Q</u>	F	N	<u>P</u>	S	<u>Y</u>	H	P		
H	A	C	S	<u>Q</u>	F	N	<u>P</u>	S	<u>Y</u>	H	P		
H	A	C	I	<u>Q</u>	F	L	D	<u>P</u>	T	<u>Y</u>	H	P	
H	P	R	L	<u>Q</u>	L	D	<u>P</u>	T	T	W			
T	A	H	R	<u>F</u>	H	<u>C</u>	<u>T</u>	S	<u>P</u>	S	V	R	P
I	A				A	F	<u>Q</u>						
UL42 (171-76) Q G T P D V													

Fig. 7. Alignment of peptide display sequences with UL42. The top two lines give sequences of peptides identified by flagellar display while the remaining peptides were identified by phage display. Underlined residues are shared with a segment of UL42 shown in the bottom line.

INTERNATIONAL SEARCH REPORT

Inte: nai Application No

PCT/US 00/12888

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07C237/24 C07D233/54 A61K31/16 A61K31/4164 A61P31/00
 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, BEILSTEIN Data, WPI Data, PAJ, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	J.M- TRAVINS ET AL.: "Design and enantioselective synthesis of a peptidomimetic of the Helix-Turn-Helix DNA-binding Protein motif" JOURNAL OF ORGANIC CHEMISTRY, vol. 62, 1997, pages 8387-8393, XP002147825 EASTON US page 8387 -----	1
A	WO 96 41010 A (NEXSTAR PHARMACEUTICALS INC ;GOLD LARRY (US); JAYASENA SUMEDHA (US) 19 December 1996 (1996-12-19) claims -----	1

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

27 September 2000

11/10/2000

Name and mailing address of the ISA

Authorized officer

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3018

Pauwels, G

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/12888

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9641010	A 19-12-1996	US 5693502 A		02-12-1997
		US 5874557 A		23-02-1999
		US 5763173 A		09-06-1998
		AU 6159896 A		30-12-1996
		CA 2223078 A		19-12-1996
		EP 0833944 A		08-04-1998
		JP 11507223 T		29-06-1999
		US 6020130 A		01-02-2000

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)